Breaking News, Collaborations & Alliances

Marina Biotech, Mirna Therapeutics Amend microRNA Pact

Mirna gains additional rights to lead program

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Marina Biotech, Inc. and Mirna Therapeutics, Inc. have amended their license agreement for the development and commercialization of microRNA-based therapeutics using Mirna’s microRNAs and Marina Biotech’s SMARTICLESliposomal delivery technology. Under the amendment, Mirna made certain pre-payments to Marina and now has additional rights to its lead program, MRX34, currently in Phase I development in unresectable primary liver cancer or metastatic liver cancer. Also, Mirna has optioned exclusivit...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters